Open Access
| Numéro |
Med Sci (Paris)
Volume 36, Numéro 2, Février 2020
|
|
|---|---|---|
| Page(s) | 112 - 115 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/2020006 | |
| Publié en ligne | 4 mars 2020 | |
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 ; 363 : 711–723. [Google Scholar]
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 ; 366 : 2443–2454. [Google Scholar]
- Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 ; 366 : 2455–2465. [Google Scholar]
- Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 2018 ; 118 : 9–16. [CrossRef] [PubMed] [Google Scholar]
- Perrot I, Michaud HA, Giraudon-Paoli M, et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 2019 ; 27 : 2411–25 e9. [Google Scholar]
- de Andrade Mello P, Coutinho-Silva R, Savio LEB. Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor-host interaction and therapeutic perspectives. Front Immunol 2017; 8 : 1526. [CrossRef] [PubMed] [Google Scholar]
- Silva-Vilches C, Ring S, Mahnke K. ATP and its metabolite adenosine as regulators of dendritic cell activity. Front Immunol 2018 ; 9 : 2581. [CrossRef] [PubMed] [Google Scholar]
- Bastid J, Regairaz A, Bonnefoy N, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 2015 ; 3 : 254–265. [CrossRef] [PubMed] [Google Scholar]
- Sun X, Wu Y, Gao W, et al. CD39/ENTPD1 expression by CD4+ Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterol 2010 ; 139 : 1030–1040. [CrossRef] [Google Scholar]
- Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011 ; 71 : 2892–2900. [Google Scholar]
- Stagg J, Beavis PA, Divisekera U, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012 ; 72 : 2190–2196. [Google Scholar]
- Antonioli L, Yegutkin GG, Pacher P, et al. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer 2016 ; 2 : 95–109. [CrossRef] [PubMed] [Google Scholar]
- Antonioli L, Novitskiy SV, Sachsenmeier KF, et al. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov Today 2017 ; 22 : 1686–1696. [CrossRef] [PubMed] [Google Scholar]
- Nikolova M, Carriere M, Jenabian MA, et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011 ; 7 : e1002110. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.